26th week of 2010 patent applcation highlights part 58 |
Patent application number | Title | Published |
20100168164 | Antidiabetic Oxazolidinediones and Thiazolidinediones - Phenoxyphenyl and phenoxybenzyl oxazolidine-2,4-diones and thiazolidine-2,4-diones are agonists or partial agonists of PPAR gamma and are useful in the treatment and control of hyperglycemia that is symptomatic of type II diabetes, as well as dyslipidemia, hyperlipidemia, hypercholesterolemia, hypertriglyceridemia, and obesity that are often associated with type 2 diabetes. | 2010-07-01 |
20100168165 | METHOD OF TREATING DISEASE INVOLVING MYELIN AND/OR AXONAL LOSS - Disclosed is a method of treating a disease involving myelin and/or axonal loss, such as a demyelinating disease, in a mammal comprising administering a compound of formula I | 2010-07-01 |
20100168166 | Method of Providing An Antihistaminic Effect in a Hepatically Impaired Patient - The present invention relates to a method of providing an antihistaminic effect in a hepatically impaired patient in need thereof comprising administering to said patient an effective antihistaminic amount of a compound of the formula | 2010-07-01 |
20100168167 | Piperidinones Useful in the Treatment of Inflammation - There is provided compounds of formula (I): wherein R | 2010-07-01 |
20100168168 | Aminoaryl sulphonamide derivatives as functional 5-HT6 ligands - The present invention provides aminoaryl sulphonamide derivatives of formula (I), useful in the treatment of a CNS disorder related to or affected by the 5-HT | 2010-07-01 |
20100168169 | SUBSTITUTED 1,3-DIOXANES USEFUL AS PPAR MODULATORS - Specifically useful stereoisomers of 1,3-dioxane derivatives are described and their use in the treatment of a disease or condition dependent on PPAR modulation, such as diabetes, cancer, inflammation, neurodegenerative disorders and infections as well as their use in the treatment of a disease related to TP, such as cardiovascular diseases. | 2010-07-01 |
20100168170 | Piperidinones Useful in the Treatment of Inflammation - There is provided compounds of formula (I), wherein R | 2010-07-01 |
20100168171 | Piperidinone Carboxamide Derivatives as P2X7 Modulators - The present invention relates to a compound of formula (I) or a pharmaceutically acceptable salt thereof: | 2010-07-01 |
20100168172 | HETEROARYL (SUBSTITUTED)ALKYL N-SUBSTITUTED SULFOXIMINES AS INSECTICIDES - N-Substituted heteroaryl (substituted)alkyl sulfoximines are effective at controlling insects. | 2010-07-01 |
20100168173 | HETEROCYCLES SUBSTITUTED PYRIDINE DERIVATIVES AND ANTIFUNGAL AGENT CONTAINING THEREOF - An object of the present invention is to provide an antifungal agent which has excellent antifungal effects and is superior in terms of its physical properties, safety and metabolic stability. According to the present invention, there is disclosed a compound represented by the following formula (I), or a salt thereof: | 2010-07-01 |
20100168174 | Combination of AMPA Receptor Antagonists and Acetylcholinesterase Inhibitors for the Treatment of Neuropathic Pain - The invention provides methods for treating and/or preventing neuropathic pain by administering to patients in need thereof therapeutically effective amounts of AMPA receptor antagonists; and cholinesterase inhibitors and/or anti-neuropathic pain agents. The neuropathic pain may be painful diabetic neuropathy. The invention also provides kits, and pharmaceutical compositions comprising therapeutically effective amounts of AMPA receptor antagonists; and cholinesterase inhibitors and/or anti-neuropathic pain agents. The AMPA receptor antagonists may be, for example, 3-(2-cyanophenyl)-5-(2-pyridyl)-1-phenyl-1,2-dihydropyridin-2-one. The cholinesterase inhibitor may be, for example, 1-benzyl-4-((5,6-dimethoxy-1-indanon)-2-yl)methylpiperidine (donepezil). | 2010-07-01 |
20100168175 | ATPENINS - The present invention relates to processes for preparing certain 2-pyridones and 2-pyridinols, to novel compounds of these two types and to their use as biologically active compounds, in particular for controlling harmful microorganisms in crop protection, in the medicinal field and in the protection of materials. | 2010-07-01 |
20100168176 | NOVEL COMPOUNDS, PHARMACEUTICAL COMPOSITIONS CONTAINING SAME, AND METHODS OF USE FOR SAME - Compounds having the following general formula, pharmaceutical compositions comprising the compounds, and methods of treating cancer, obesity, and microbial infections using such compositions: wherein: R1=H, C1-C20 alkyl, cycloalkyl, alkenyl, aryl, arylalkyl, or alkylaryl, cyanomethyl, —OCH3, OC(O)CH3 or OC(O)CF3 R2=-OCH2C(O)NHNH—R5, where R5 is (a) phenyl, optionally substituted with one or more of halogen, C1-C8 alkyl, optionally substituted with halogen, —OH, —OR6, where R6 is C1-C8 alkyl, optionally substituted with halogen, or (b) 2-, 3-, or 4-pyridyl, optionally substituted with halogen, —OH, —OR6, where R6 is C1-C8 alkyl, optionally substituted with halogen, or (c) a heterocycle selected from the group consisting of imidazole, thiazole, benzimidazole, benzoxazole, benzthiazole, tetrazole, triazole, and aminothiazole; or (d) —C(O)R7, where R7 is a C1-C20 alkyl, cycloalkyl, alkenyl, aryl, arylalkyl, or alkylaryl, or a heterocycle selected from the group consisting of pyridyl, imidazole, thiazole, benzimidizole, benzoxazole, benzthiazole, tetrazole, triazole, and aminothiazole; and R3 and R4, the same or different from each other, are C1-C20 alkyl, cycloalkyl, alkenyl, aryl, arylalkyl, or alkylaryl. | 2010-07-01 |
20100168177 | Stable insecticide compositions - Insect controlling compositions including an N-substituted (6-haloalkylpyridin-3-yl)alkyl sulfoximine compound and an organic acid or a salt thereof exhibit increased stability. | 2010-07-01 |
20100168178 | Stable insecticide compositions and methods for producing same - Insect controlling compositions including an N-substituted (6-haloalkylpyridin-3-yl)alkyl sulfoximine compound exhibiting increased stability, along with methods for preparing same, are disclosed. | 2010-07-01 |
20100168179 | 6-ALKENYL-, 6-ALKINYL- AND 6-EPOXY-EPOTHILONE DERIVATIVES, PROCESS FOR THEIR PRODUCTION, AND THEIR USE IN PHARMACEUTICAL PREPARATIONS - This invention describes the new 6-alkenyl- and 6-alkinyl-epothilone derivatives of general formula (I) in which R | 2010-07-01 |
20100168180 | Novel Compounds - A compound for use in the treatment of proliferative disorders, such as cancer, having the following formula: | 2010-07-01 |
20100168181 | BENZIMIDAZOLE AMIDO DERIVATIVES, THEIR MANUFACTURE AND USE AS PHARMACEUTICAL AGENTS - Objects of the present invention are the compounds of formula (I) their pharmaceutically acceptable salts, enantiomeric forms, diastereoisomers and racemates, the preparation of the above-mentioned compounds, medicaments containing them and their manufacture, as well as the use of the above-mentioned compounds in the control or prevention of illnesses such as cancer. | 2010-07-01 |
20100168182 | COMPOUNDS AND COMPOSITIONS AS KINASE INHIBITORS - The invention provides a novel class of compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with abnormal or deregulated kinase activity, particularly TrkA, TrkB, TrkC, PDGFR and c-kit. | 2010-07-01 |
20100168183 | SUBSITUTED CYCLIC COMPOUND, ITS PREPARATION PROCESS AND ITS MEDICAL USE - The present invention provides a substituted cyclic compound of the following general formula I or II: | 2010-07-01 |
20100168184 | SMALL MOLECULE BCL-X1/BCL-2 BINDING INHIBITORS - Bcl-xL/Bcl-2 binding inhibitors useful in the treatment of unwanted proliferating cells, including cancers and precancers, in subjects in need of such treatment. Also provided are methods of treating a subject having unwanted proliferating cells comprising administering a therapeutically effective amount of a Bcl-xL/Bcl-2 binding inhibitor described herein to a subject in need of such treatment. Also provided are methods of preventing the proliferation of unwanted proliferating cells, such as cancers and precancers, in a subject comprising the step of administering a therapeutically effective amount of a Bcl-xL/Bcl-2 binding inhibitor described herein to a subject at risk of developing a condition characterized by unwanted proliferating cells. | 2010-07-01 |
20100168185 | Use of 5-pyridin-4-yl-1,3-thiazoles for controlling phytopathogenic fungi - The present invention relates to the use of known 5-pyridin-4-yl-1,3-thiazoles for controlling phytopathogenic fungi in plants and parts of plants, and also to methods for controlling phytopathogenic fungi in plants and parts of plants in crop protection, and also to crop protection compositions comprising these 5-pyridin-4-yl-1,3-thiazoles. | 2010-07-01 |
20100168186 | Pre-Mixed, Ready-To-Use Pharmaceutical Compositions - Provided herein are ready-to-use premixed pharmaceutical compositions of nicardipine or a pharmaceutically acceptable salt and methods for use in treating cardiovascular and cerebrovascular conditions. | 2010-07-01 |
20100168187 | THERAPEUTIC COMBINATION - This invention relates to pharmaceutical combinations of amlodipine or a pharmaceutically acceptable acid addition salt thereof and atorvastatin or a pharmaceutically acceptable salt thereof, kits containing such combinations and methods of using such combinations to treat subjects suffering from angina pectoris, atherosclerosis, combined hypertension and hyperlipidemia and to treat subjects presenting with symptoms of cardiac risk, including humans. This invention also relates to additive and synergistic combinations of amlodipine and atorvastatin whereby those synergistic combinations are useful in treating subjects suffering from angina pectoris, atherosclerosis, combined hypertension and hyperlipidemia and those subjects presenting with symptoms of cardiac risk, including humans. | 2010-07-01 |
20100168188 | Estrogen Receptor Modulators - The present invention relates to compounds and derivatives thereof, their synthesis, and their use as estrogen receptor modulators. The compounds of the instant invention are ligands for estrogen receptors and as such may be useful for treatment or prevention of a variety of conditions related to estrogen functioning including: bone loss, bone fractures, osteoporosis, metastatic bone disease, Paget's disease, periodontal disease, cartilage degeneration, endometriosis, uterine fibroid disease, hot flashes, increased levels of LDL cholesterol, cardiovascular disease, impairment of cognitive functioning, cerebral degenerative disorders, restenosis, gynecomastia, vascular smooth muscle cell proliferation, obesity, incontinence, inflammation, inflammatory bowel disease, sexual dysfunction, hypertension, retinal degeneration and cancer, in particular of the breast, uterus and prostate. | 2010-07-01 |
20100168189 | THERAPEUTIC SUBSTITUTED LACTAMS - Therapeutic compounds, compositions, methods, and medicaments related thereto are disclosed herein. | 2010-07-01 |
20100168190 | Novel azoles and related derivatives as non-nucleoside reverse transcriptase inhibitors (nnrtis) in antiviral therapy (hiv) - The present invention relates to novel heterocyclic compounds, including oxadiazole compounds, pharmaceutical compositions and their use in the inhibition of reverse transcriptase and the treatment of HIV (1 and 2) infections, AIDS and ARC and other viral infections. | 2010-07-01 |
20100168191 | PHARMACEUTICAL FORMULATION COMPRISING PRAMIPEXOLE - The present invention refers to the use of a medicament for the paediatric treatment of RLS and/or Tic Disorder and/or Tourette's Syndrom. | 2010-07-01 |
20100168192 | BENZISOXAZOLE DERIVATIVES AS POTASSIUM CHANNEL MODULATORS FOR THE TREATMENT OF E.G. RESPIRATORY DISEASES, EPILEPSY AND CONVULSIONS - This invention relates to novel benzisoxazole derivatives that are found to be potent modulators of potassium channels and, as such, are valuable candidates for the treatment of diseases or disorders as diverse as those which are responsive to the modulation of potassium channels e.g. a respiratory disease, epilepsy or convulsions. X represents a substituent selected from the group consisting of CO—NR′R″, CO—O—R′, CO—NH—S, CO—NH—SO | 2010-07-01 |
20100168193 | THERAPEUTIC USE OF IMIDAZOLE-5-CARBOXYLIC ACID DERIVATIVES - The invention discloses the use of 2-butyl-4-chloro-1-[2′-(1H-tetrazol-5-yl)1,1′-biphenyl-methyl]-imidazole-5-carboxylic acid, 1-[(isopropoxycarbonyl)oxy] methyl ester and the pharmaceutically acceptable salts thereof in the manufacture of a medicament for the treatment of the damage of a target organ caused by hypertension. It particularly discloses the use of this compound in the manufacture of a medicament for the treatment of left ventricular hypertrophy, renal dysfunction, aorta thickening caused by hypertension, which provides an effective drug and method for the treatment of the damage of target organs for hypertension patients. | 2010-07-01 |
20100168194 | Amino-5-[4-(difluoromethoxy)phenyl]-5-phenylimidazolone Compounds For The Inhibition Of Beta-secretase - The present invention provides compounds and methods for the use thereof to inhibit β-secretase (BACE) and treat β-amyloid deposits and neurofibrillary tangles. | 2010-07-01 |
20100168195 | DERIVATIVES AND ANALOGS OF CHROMAN AS FUNCTIONALLY SELECTIVE ALPHA2C ADRENORECEPTOR AGONISTS - In its many embodiments, the present invention provides a novel class of chroman compounds of formula I as α2C adrenergic receptor agonists, methods of preparing such compounds, pharmaceutical compositions containing one or more such compounds, methods of prepaxing pharmaceutical formulations comprising one or more such compounds, and methods of treatment, prevention, inhibition, or amelioration of one or more conditions associated with the α2C adrenergic receptors using such compounds or pharmaceutical compositions. | 2010-07-01 |
20100168196 | N-Substituted (Benzoimidazol-2-yl)phenylamines, Processes for Their Preparation, Their Use as a Medicament or Diagnostic Aid, and a Medicament Comprising Them - This invention is directed to the compound of formula (I), compositions containing said compounds to inhibit the sodium-proton exchanger of subtype 3 (NHE3) which are useful in the prevention or treatment of various disorders in a patient suffering from a disease state, such as, renal disorders including acute or chronic renal failure, disorders of biliary function and for respiratory disorders such as snoring or sleep apnea or for stroke. | 2010-07-01 |
20100168197 | MUSCARINIC RECEPTOR ANTAGONISTS - This present invention generally relates to muscarinic receptor antagonists, which are useful, among other uses, for the treatment of various diseases of the respiratory, urinary and gastrointestinal systems mediated through muscarinic receptors. The invention also relates to the process for the preparation of disclosed compounds, pharmaceutical compositions containing the disclosed compounds, and the methods for treating diseases mediated through muscarinic receptors. | 2010-07-01 |
20100168198 | Mitochondria-targeted antioxidant prodrugs and methods of use - The present invention is a mitochondria-targeted antioxidant prodrug useful for the prevention or treatment of diseases or conditions associated with mitochondrial dysfunction resulting from changes in the mitochondrial redox environment. Antioxidant prodrugs of the invention are produced by modifying an antioxidant to a fatty acid so that the resulting prodrug is targeted to and activated by an enzyme of mitochondrial fatty acid beta-oxidation. | 2010-07-01 |
20100168199 | Kinase Inhibitors - The present invention relates to organic molecules capable of modulating tyrosine kinase signal transduction in order to regulate, modulate and/or inhibit abnormal cell proliferation. | 2010-07-01 |
20100168200 | ANTIFUNGAL PHARMACEUTICAL COMPOSITION - Disclosed is an antifungal agent for external use, which is characterized by containing a compound represented by the general formula (1), 50 to 95 mass % of an alcohol such as ethanol, 0.1 to 35 mass % of water or the like, and 0.01 to 5 mass % of a cellulose thickening agent. X is a halogen or H. | 2010-07-01 |
20100168201 | Polymorphs of [R-(R*, R*) ]-2-(4-Fluorophenyl)-Beta, Delta-Dihydroxy-5-(1-Methylethyl)-3-Phenyl-4-[(Phenylamino)Carbonyl]-1H-P- yrrole-1-Heptanoic Acid Magnesium Salt (2:1) - Crystalline and amorphous polymorphic forms of Atorvastatin magnesium and processes for their preparation are claimed. | 2010-07-01 |
20100168202 | RAD 9 AS A DIAGNOSTIC,PROGNOSTIC,AND THERAPEUTIC TOOL FOR PROSTATE CANCER - This disclosure provides a method of treating a human subject having a cancer which comprises administering to the subject a nucleic acid so as to inhibit expression of human RAD9 protein in a cell of the cancer so as to thereby treat the human subject. This disclosure also provides methods of assessing gains in prostate cancer therapy and detecting prostate cancer. | 2010-07-01 |
20100168203 | ADENYLYL CYCLASES AS NOVEL TARGETS FOR ANTIBACTRIAL INTERVENTIONS - The present invention relates to a method of preventing or treating a disease caused by bacterial infection by administering an effective amount of a modulator of bacterial adenylyl cyclase. The invention also provides pharmaceutical compositions useful for preventing or treating a disease, with the compositions containing a therapeutically effective amount of a modulator of bacterial adenylyl cyclase. The invention also provides screening methods for identifying selective modulators of bacterial adenylyl cyclase that do not substantially modulate adenylyl cyclase of the subject. The invention also provides methods for culturing bacterial pathogens and methods for inducing the pathogenic state in vitro. | 2010-07-01 |
20100168204 | Therapeutic uses of inhibitors of RTP801L - The present invention provides novel molecules, compositions, methods and uses for treating microvascular disorders, eye diseases respiratory conditions and hearing disorders based upon inhibition of the RTP801L gene and/or protein. | 2010-07-01 |
20100168205 | Methods and Compositions for Prevention or Treatment of RSV Infection Using Modified Duplex RNA Molecules - Methods and compositions are provided for the prevention or treatment of RSV infection in a human. The methods include administering one or more doses of a composition comprising an siRNA. The dose can be formulated for topical or parenteral administration. Topical administration includes administration as a nasal spray, or by inhalation of respirable particles or droplets. The siRNA preferably comprises a sense strand and antisense strand with modified nucleotides. | 2010-07-01 |
20100168206 | GNAQ Targeted dsRNA Compositions And Methods For Inhibiting Expression - The invention relates to a double-stranded ribonucleic acid (dsRNA) targeting a G-alpha q subunit (GNAQ) of a heterotrimeric G gene, and methods of using the dsRNA to inhibit expression of GNAQ. | 2010-07-01 |
20100168207 | COMPOSITIONS AND METHODS FOR SIRNA INHIBITION OF ANGIOGENESIS - RNA interference using small interfering RNAs which are specific for the vascular endothelial growth factor (VEGF) gene and the VEGF receptor genes Flt-1 and Flk-1/KDR inhibit expression of these genes. Diseases which involve angiogenesis stimulated by overexpression of VEGF, such as diabetic retinopathy, age related macular degeneration and many types of cancer, can be treated by administering the small interfering RNAs. | 2010-07-01 |
20100168208 | RNA INTERFERENCE MEDIATED TREATMENT OF ALZHEIMER'S DISEASE USING SHORT INTERFERING NUCLEIC ACID (siNA) - The present invention concerns methods and reagents useful in modulating BACE gene expression in a variety of applications, including use in therapeutic, diagnostic, target validation, and genomic discovery applications. Specifically, the invention relates to small nucleic acid molecules, such as short interfering nucleic acid (siNA), short interfering RNA (siRNA), double-stranded RNA (dsRNA), micro-RNA (miRNA), and short hairpin RNA (shRNA) molecules capable of mediating RNA interference (RNAi) against beta-secretase (BACE), amyloid precursor protein (APP), pin-1, presenillin 1 (PS-1) and/or presenillin 2 (PS-2) gene expression and/or activity. The small nucleic acid molecules are useful in the treatment of Alzheimer's disease and any other condition that responds to modulation of BACE, APP, pin-1, PS-1 and/or PS-2 expression or activity. | 2010-07-01 |
20100168209 | APOPTOSIS INDUCER FOR CANCER CELL - The present invention revealed that by suppressing the expression of the WRN gene, the BLM gene, or the RecQ1 gene, which belong to the RecQ helicase family, apoptosis is induced in various cancer cells and their proliferation is suppressed. Compounds that suppress the expression of RecQ helicase family genes or the functions of RecQ helicase proteins are thought to have the activity of inducing apoptosis. | 2010-07-01 |
20100168210 | T-Cell Cytokine-Inducing Surface Molecules and Methods of Use - The invention provides cytokine modulators and methods for using the same to modulate cytokine production in monocyte lineage-derived cells. In particular, cytokine modulators of the invention selectively bind to a T-cell cytokine-inducing surface molecule (TCISM)-ligand of T lymphocytes or the corresponding TCISM-receptor of monocyte lineage-derived cells, thereby modulating cytokine production in monocyte lineage-derived cells. | 2010-07-01 |
20100168211 | HEREDITARY CATARACT STATUS IN CANINES BASED ON HSF4 GENE MARKER - The invention provides methods for assessing the Hereditary cataract (HC) status of a canine mammal, which methods comprise use of an HSF4 marker to assess the status. Preferred canine mammals are dogs selected from the following breeds: Staffordshire bull terrier, Boston terrier, French bulldog, Mastiff, Bulldog, Boxer, Bullmastiff, Miniature bull terrier. | 2010-07-01 |
20100168212 | OLIGOMERS - Molecules are provided for inducing or facilitating exon skipping in forming spliced mRNA products from pre-mRNA molecules in cells. The molecules may be provided directly as oligonucleotides or expression products of vectors that are administered to a subject. High rates of skipping can be achieved. High rates of skipping reduce the severity of a disease like Duchene Muscular Dystrophy so that the disease is more like Becker Muscular Dystrophy. This is a severe reduction in symptom severity and mortality. | 2010-07-01 |
20100168213 | Protein-coding RNA to correct mitochondrial dysfunction - The present invention provides compositions and methods for using correctional RNA, with a proteinaceous carrier, to stimulate respiration of the cells, tissues, organs or the whole organism of normal or diseased subjects. In one embodiment of the invention, the signal-tagged correctional RNA is one or more protein-coding RNAs (pcRNA) that encode one or more of human mitochondrial proteins. The invention specifically provides a broad-spectrum formulation applicable to a wide variety of disorders that are associated with mitochondrial mutations. | 2010-07-01 |
20100168214 | NUCLEIC ACID AND CORRESPONDING PROTEIN ENTITLED 151P3D4 USEFUL IN TREATMENT AND DETECTION OF CANCER - A novel gene (designated 151P3D4) and its encoded protein, and variants thereof, are described wherein 151P3D4 exhibits tissue specific expression in normal adult tissue, and is aberrantly expressed in the cancers listed in Table I. Consequently, 151P3D4 provides a diagnostic, prognostic, prophylactic and/or therapeutic target for cancer. The 151P3D4 gene or fragment thereof, or its encoded protein, or variants thereof, or a fragment thereof, can be used to elicit a humoral or cellular immune response; antibodies or T cells reactive with 151P3D4 can be used in active or passive immunization. | 2010-07-01 |
20100168215 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF NEUROLOGICAL DISEASE - The present invention relates to a method for delivering a nucleic acid sequence encoding neuropeptide Y, or a derivative or functional fragment thereof, to a mammalian nervous system target cell. The expression of exogenous NPY, or a derivative or a functional fragment thereof in the target cell(s) provides therapeutic benefit for subjects afflicted with a neurological disorder. | 2010-07-01 |
20100168216 | PROSTAGLANDIN PHARMACEUTICAL COMPOSITIONS - The present invention relates to new prostaglandin derivatives having improved pharmacological activity and enhanced tolerability. They can be employed for the treatment of glaucoma and ocular hypertension. | 2010-07-01 |
20100168217 | SULFAMATOBENZOTHIOPHENE DERIVATIVES - The invention relates to novel compound of the general formula (I), in which R has the meanings indicated in claim | 2010-07-01 |
20100168218 | METHOD OF REDUCING FOOD INTAKE - A method of decreasing the food intake of a subject, comprising the administration of a compound which increases FAO, where the compound does not act in the central nervous system to decrease appetite, where the compound is not a fatty acid, or an NPY-inhibitor, or an FAS inhibitor. | 2010-07-01 |
20100168219 | Chronic inflammation and transplantation - Neutrophils (PMN) can migrate along gradients of chemoattractants across endothelial monolayers to sites of inflammation and infection. This chemotaxis through endothelial cell borders is involved in several acute and chronic inflammatory diseases, however our understanding of the role of endothelial second messengers in the regulation of leukocyte emigration is still incomplete. We investigated this using an in vitro model of neutrophil migration across human umbilical vein endothelial cells (HUVECs) and human microvascular endothelial cells (HMECs) on cell culture inserts. We report that activation of endothelial protein kinase C (PKC) by both phorbol myristate acetate (PMA) and Bryostatin-1 (a potent PKCδ and c activator) can completely abolish neutrophil migration mediated by both endothelial TNF-α stimulation and a leukotriene B4 (LTB | 2010-07-01 |
20100168220 | PLANT EXTRACT COMPOSITION FOR TREATING HEPATITIS C - The invention provides a plant extract composition for treating hepatitis C, including an effective amount of the proanthocyanidins oligomer extracted from a plant material, and a pharmaceutically acceptable carrier or salt, wherein the structure of proanthocyanidins is shown as follows: | 2010-07-01 |
20100168221 | PHARMACEUTICAL COMPOSITION FOR TREATING HEPATITIS B VIRUS AND HEALTH FOOD PRODUCT HAVING HEPATITIS B VIRUS INHIBITING EFFECTS - The invention provides a pharmaceutical composition for treating hepatitis B, including: an effective amount of proanthocyanidins; and a pharmaceutically acceptable carrier or salt, wherein a formula of the monomer of the proanthocyanidins is shown in the following: | 2010-07-01 |
20100168222 | NOVEL USE OF SARGACHROMENOL - The present invention relates to novel use of sargachromenol, and more particularly, the present invention relates to novel use of sargachromenol for destroying and/or lysing hyperproliferating keratinocyte. Accordingly, since sargachromenol of the present invention has activity in destroying and/or lysing keratinocyte, it may be useful for keratinocyte lysing agents in the skin area where the keratinocytes are hyperproliferating or peeling agents. | 2010-07-01 |
20100168223 | 7-Hydroxy Chromones As Potent Antioxidants - The present invention describes the identification and purification of 7-hydroxychromes that exhibit potent antioxidant activity. In one embodiment the present invention includes a method for providing an antioxidant to a host in need thereof, comprising administering an effective amount of a 7-hydroxychrome or a mixture of 7-hydroxychromones. The present invention includes methods that are effective in inhibiting free radical and oxidation caused damage through the simultaneous suppression of free radical generation and the suppression of the production of reactive oxygen species (ROS). The present invention also includes methods for preventing and treating ROS mediated diseases and conditions and diseases and conditions associated with other oxidative processes. The method for preventing and treating ROS mediated diseases and conditions and diseases and conditions associated with other oxidative processes is comprised of administering to a host in need thereof an effective amount of a composition comprised of a 7-hydroxychrome or a mixture of 7-hydroxychromones and a pharmaceutically acceptable carrier. Included in this invention is an improved method to isolate and purify 7-hydroxychromones from plant sources. | 2010-07-01 |
20100168224 | Hypoglycemic Activity of Osthole - The present invention relates to a method for controlling blood glucose level and a method for the prophylaxis or treatment of diabetes mellitus and/or its complications. The present invention further relates to an anti-diabetic formulation for controlling blood glucose level and/or for the prophylaxis or treatment of diabetes mellitus and/or its complications. | 2010-07-01 |
20100168225 | Small-Molecule Hepatitis C Virus (HCV) NS3/4A Serine Protease Inhibitors - Compounds of Formula 5 and prodrug compounds of Formula 5 wherein G | 2010-07-01 |
20100168226 | SPIROCYCLIC TETRONIC ACID DERIVATIVES - The present invention relates to novel spirocyclic tetronic acid derivatives of the formula (I) | 2010-07-01 |
20100168227 | Preventative Treatment and Remission of Allergic Diseases - The invention provides the use of at least one plant selected from plants of the family Zingiberaceae in the preparation of a medicament for use in the treatment or prophylaxis of allergic diseases. The plant is optionally selected from the genera | 2010-07-01 |
20100168228 | NOVEL CHEMOTHERAPEUTIC AGENTS AGAINST INFLAMMATION AND CANCER - Novel compounds, their methods of preparation and use in therapies related to cancer and inflammation are provided. Compounds comprise esters of cinnamic acid, vanillic acid and 4-hydroxy cinnamic acid and derivatives and salts thereof. Compounds with novel benzofuran lignan structure as a potent antimitotic agent and inducer of apoptosis are provided. Formulations and methods for treatment of diseases mediated by NF-kappaB are also provided. | 2010-07-01 |
20100168229 | Process for the preparation of optically active compounds using transfer hydrogenation - A catalytic process for the preparation of optically active compounds and their conversion thereafter to desired drug substances. In particular, the process relates to the preparation of (S)-3-(1-Dimethylamino-ethyl)-phenol using asymmetric catalytic reduction and transfer hydrogenation, thereby providing an improved route to forming drug substances such as rivastigimine and rivastigimine hydrogen tartrate. | 2010-07-01 |
20100168230 | Methods for Making Organozinc Salts and Compositions Containing the Same - Organic zinc salts and mixtures thereof, organic zinc salt coated particles, methods of preparing organic zinc salts and organic zinc salt coated particles, and various applications of such coated particles, including applications in rubber, other polymeric materials, and pesticides and/or fungicides are disclosed. | 2010-07-01 |
20100168231 | TARGET ENZYME FOR THE TREATMENT OF ACNE - The use of an enzyme as a research tool for acne, by identifying a compound for the treatment of acne and/or any disorder associated with cutaneous hyperseborrhoea. | 2010-07-01 |
20100168232 | Oligomer-Anticholinergic Agent Conjugates - The invention provides anticholinergic agents that are chemically modified by covalent attachment of a water-soluble oligomer. A conjugate of the invention, when administered by any of a number of administration routes, exhibits characteristics that are different as compared to the characteristics of the anticholinergic agent not attached to the water-soluble oligomer. | 2010-07-01 |
20100168233 | TERBINAFINE FORMULATION - The present invention provides a pharmaceutical composition comprising as the active agent a terbinafine compound, water, and at least one water-soluble or water-miscible nonionic surfactant, wherein the terbinafine compound has at least one form selected from the group consisting of free base form, acid addition salt form, ionic form, and combinations thereof; and wherein substantially no alcohol is present. | 2010-07-01 |
20100168234 | PRODUCTION OF PERACIDS USING AN ENZYME HAVING PERHYDROLYSIS ACTIVITY - A process is provided for producing peroxycarboxylic acids from carboxylic acid esters. More specifically, carboxylic acid esters are reacted with an inorganic peroxide, such as hydrogen peroxide, in the presence of an enzyme catalyst having perhydrolysis activity. The present perhydrolase catalysts are classified as members of the carbohydrate esterase family 7 (CE-7) based on the conserved structural features. Further, disinfectant formulations comprising the peracids produced by the processes described herein are provided. | 2010-07-01 |
20100168235 | PRODUCTION OF PERACIDS USING AN ENZYME HAVING PERHYDROLYSIS ACTIVITY - A process is provided for producing peroxycarboxylic acids from carboxylic acid esters. More specifically, carboxylic acid esters are reacted with an inorganic peroxide, such as hydrogen peroxide, in the presence of an enzyme catalyst having perhydrolysis activity. The present perhydrolase catalysts are classified as members of the carbohydrate esterase family 7 (CE-7) based on the conserved structural features. Further, disinfectant formulations comprising the peracids produced by the processes described herein are provided. | 2010-07-01 |
20100168236 | PRODUCTION OF PERACIDS USING AN ENZYME HAVING PERHYDROLYSIS ACTIVITY - A process is provided for producing peroxycarboxylic acids from carboxylic acid esters. More specifically, carboxylic acid esters are reacted with an inorganic peroxide, such as hydrogen peroxide, in the presence of an enzyme catalyst having perhydrolysis activity. The present perhydrolase catalysts are classified as members of the carbohydrate esterase family 7 (CE-7) based on the conserved structural features. Further, disinfectant formulations comprising the peracids produced by the processes described herein are provided. | 2010-07-01 |
20100168237 | PRODUCTION OF PERACIDS USING AN ENZYME HAVING PERHYDROLYSIS ACTIVITY - A process is provided for producing peroxycarboxylic acids from carboxylic acid esters. More specifically, carboxylic acid esters are reacted with an inorganic peroxide, such as hydrogen peroxide, in the presence of an enzyme catalyst having perhydrolysis activity. The present perhydrolase catalysts are classified as members of the carbohydrate esterase family 7 (CE-7) based on the conserved structural features. Further, disinfectant formulations comprising the peracids produced by the processes described herein are provided. | 2010-07-01 |
20100168238 | PHARMACEUTICAL COMPOSITION CONTAINING PHLOROGLUCINOL AND PARACETAMOL - The invention relates to a pharmaceutical composition for oral or rectal administration, that contains phloroglucinol and paracetamol in a pharmaceutically acceptable carrier. The inventors have evidenced a synergy developed by these two active ingredients in antispasmodic therapy. | 2010-07-01 |
20100168239 | Use of Rasagiline for the Treatment of Multiple System Atrophy - Disclosed is a method for the treatment of Multiple System Atrophy comprising administering to a subject an amount of R(+)-N-propargyl-1-aminoindan or a pharmaceutically acceptable salt thereof. | 2010-07-01 |
20100168240 | SUBSTITUTED DIBENZOIC ACID DERIVATIVES AND USE THEREOF - The invention relates to novel substituted dibenzoic acid derivatives of formula (I), wherein A represents a group of formula (II) or (III), to methods for producing the same, and to their use in the treatment and/or prophylaxis of diseases. The invention also relates to the use of said substances in the production of drugs for the treatment and/or prophylaxis of diseases, especially in the treatment and/or prevention of cardiovascular diseases. | 2010-07-01 |
20100168241 | TREATMENT OF ACNE DISEASE STATES, NOTABLY ACNE VULGARIS - Acne disease states, notably acne vulgaris, are treated with naphthoic acid compounds and particularly adapalene in association/combination with light therapy. | 2010-07-01 |
20100168242 | Polymorphs of suberoylanilide hydroxamic acid - The present invention provides methods of selectively inducing terminal differentiation, cell growth arrest and/or apoptosis of neoplastic cells, and/or inhibiting histone deacetylase (HDAC) by administration of pharmaceutical compositions comprising potent HDAC inhibitors. The oral bioavailability of the active compounds in the pharmaceutical compositions of the present invention is surprisingly high. Moreover, the pharmaceutical compositions unexpectedly give rise to high, therapeutically effective blood levels of the active compounds over an extended period of time. The present invention further provides a safe, daily dosing regimen of these pharmaceutical compositions, which is easy to follow, and which results in a therapeutically effective amount of the HDAC inhibitors in vivo. The present invention also provides a novel Form I polymorph of SAHA, characterized by a unique X-ray diffraction pattern and Differential Scanning Calorimetry profile, as well a unique crystalline structure. | 2010-07-01 |
20100168243 | Renin Inhibitors - The present invention is directed to aspartic protease inhibitors. The present invention is also directed to pharmaceutical compositions comprising the disclosed aspartic protease inhibitors. The present invention is further directed to methods of antagonizing one or more aspartic proteases in a subject in need thereof, and methods for treating an aspartic protease mediated disorder in a subject using the disclosed aspartic protease inhibitors. | 2010-07-01 |
20100168244 | NAPHTHALENE COMPOUNDS, A PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM - Compounds of formula (I): | 2010-07-01 |
20100168245 | PREPARATION OF (R,R)-FENOTEROL AND (R,R)-OR (R,S)-FENOTEROL ANALOGUES AND THEIR USE IN TREATING CONGESTIVE HEART FAILURE - This disclosure concerns the discovery of (R,R)- and (R,S)-fenoterol analogues which are highly effective at binding β2-adrenergic receptors. Exemplary chemical structures for these analogues are provided. Also provided are pharmaceutical compositions including the disclosed (R,R)-fenoterol and fenoterol analogues, and methods of using such compounds and compositions for the treatment of cardiac disorders such as congestive heart failure and pulmonary disorders such as asthma or chronic obstructive pulmonary disease. | 2010-07-01 |
20100168246 | AMINE COMPOUNDS AND INHIBITING NEUROTRANSMITTER REUPTAKE - The invention relates to amine compounds as well as methods and materials involved in modulating neurotransmitter reuptake. Specifically, the invention provides amine compounds, methods for synthesizing amine compounds, and methods for inhibiting neurotransmitter reuptake. | 2010-07-01 |
20100168247 | SOLID COMPOSITES OF A CALCIUM RECEPTOR-ACTIVE COMPOUND - The invention encompasses solid composites of the calcium receptor-active compounds, processes for preparing the solid composites, immediate and controlled-release pharmaceutical formulations comprising the solid composites, and methods of treatment therewith. | 2010-07-01 |
20100168248 | PROCESS FOR PRODUCING ENRICHED FRACTIONS OF TETRAHYDROXYCURCUMIN AND TETRAHYDROTETRAHDROXY-CURCUMIN FROM THE EXTRACTS OF CURCUMA LONGA - A process for producing an enriched fraction of tetrahydoxycurcumin containing, tetrahydroxycurcumin, demethylcurcumin, demethylmonodemethoxycurcumin and bisd.emethoxycurcumin and colorless tetrahydroderivatives thereof. The process consists of demethylation of natural curcumins, obtained, in turn, from the organic solvent extract of turmeric from | 2010-07-01 |
20100168249 | COMPOSITION CONTAINING REDUCED COENZYME Q10, AND METHOD FOR STABILIZING THE COMPOSITION - The invention provides a composition containing reduced coenzyme Q | 2010-07-01 |
20100168250 | USE OF CYCLOHEXANEHEXOL DERIVATIVES IN THE TREATMENT OF OCULAR DISEASE - The present invention relates to methods of treating ocular diseases in a subject by administering to the subject a therapeutically effective amount of one or more cyclohexanehexol derivatives, or salts thereof, or a medicament comprising a cyclohexanehexol derivative and a pharmaceutically acceptable carrier. More specifically, the invention provides a medicament comprising at least one cyclohexanehexol derivative of formula (III) or (IV) useful in preventing or treating ocular diseases, by modulating the folding, oligomerization or aggregation of amyloid β in ocular cells. Methods of administration of these medicaments include systemic, transpleural, oral, intravenously, intraarterial, intramuscular, topical, via inhalation, transdermal, subcutaneous, intraperitoneal, gastrointestinal, and directly to the eye or tissues surrounding the eyes. | 2010-07-01 |
20100168251 | FRAGRANCE COMPOSITION FOR CORE SHELL MICROCAPSULES - The invention relates to a core shell microcapsules containing a fragrance composition which comprises, prior to encapsulation: A) 40 to 100% by weight of at least one cyclic aromachemical material with a density between 0.950 g/cm | 2010-07-01 |
20100168252 | SUGAR DERIVATIVES, METHOD FOR PREPARATION THEREOF, THEIR USE AS SURFACE-ACTIVE AGENTS - Composition (C) comprising for 100% of its mass: from 0.5% to 30% of one or more alcohols having the formula (IV): R1-OH (IV) wherein R1 represents a saturated or unsaturated, linear or branched aliphatic group, having from 8 to 36 carbon atoms, optionally substituted with one or more hydroxyl and/or groups and by 70% to 99.5% of one or more compounds having the formula (I): | 2010-07-01 |
20100168253 | Method For Selecting Perfume Ingredient, Method For Formulating Fragrance, And Preference-Enhancing Agent - The present invention provides a method for selecting a perfume ingredient that can enhance a preference therefor by continuous use from among arbitrary perfume ingredients; a perfume composition and a preference-enhancing agent that can give a high preference therefor and enhance the preference by continuous use; and a hair cleanser that can offer excellent use texture and improve the use texture by continuous use. | 2010-07-01 |
20100168254 | HYDROGEL COMPOSITION FOR THE TREATMENT OF DERMATOLOGICAL DISORDERS - The present patent application is related to a hydrogel composition which is essentially free of active drugs for the manufacture of a product for the treatment of dermatological disorders, especially perioral dermatitis, acne or seborrheic dermatitis. | 2010-07-01 |
20100168255 | METHOD FOR PRODUCING A COMPOUND WHICH HAS AT LEAST ONE ETHER GROUP - The present invention relates to a process for preparing a compound having at least one ether group, at least one ester group, at least one amino group or at least one urethane group by a1) preparing 1,2-propanediol by means of a process wherein glycerol is hydrogenated in the presence of a catalyst, glycerol being reacted to at most 95% and a 1,2-propanediol phase obtained and a2) reacting the 1,2-propanediol phase with a compound having at least one active hydrogen atom, at least one epoxide group, at least one ester group or at least one isocyanate group. The present invention relates to the compounds which can be obtained using this process and the chemical products, emulsions, cosmetic formulations, plastics material compositions and drilling compositions prepared using the compound and the use and preparations thereof. | 2010-07-01 |
20100168256 | USE OF PHOSPHORIC TRIAMIDES IN CLEANER AND HYGIENE APPLICATIONS - The present invention describes the use of phosphoric triamides in cleaner and hygiene applications. | 2010-07-01 |
20100168257 | METAL-DOPED NICKEL OXIDES AS CATALYSTS FOR THE METHANATION OF CARBON MONOXIDE - The invention relates to catalysts for the methanation of carbon monoxide, which comprise metal-doped nickel oxide of the composition (in mol %) (M1) | 2010-07-01 |
20100168258 | Preparation of Cobalt-Ruthenium/zeolite fischer-tropsch catalysts - A method for forming a cobalt-containing Fischer-Tropsch catalyst involves precipitating a cobalt oxy-hydroxycarbonate species by turbulent mixing, during which a basic solution collides with an acidic solution comprising cobalt. The method further involves depositing the cobalt oxy-hydroxycarbonate species onto an acidic support to provide a catalyst comprising cobalt and the acidic support. The acidic support comprises a zeolite, a molecular sieve, or combinations thereof. | 2010-07-01 |
20100168259 | PROMOTED CARBIDE-BASED FISCHER-TROPSCH CATALYST, METHOD FOR ITS PREPARATION AND USES THEREOF - The present invention is directed towards a precursor for a Fischer-Tropsch catalyst comprising a catalyst support, cobalt or iron on the catalyst support and one or more noble metals on the catalyst support, wherein the cobalt or iron is at least partially in the form of its carbide in the as-prepared catalyst precursor, a method for preparing said precursor and the use of said precursor in a Fischer-Tropsch process. | 2010-07-01 |
20100168260 | POROUS MATERIALS AND PROCESS FOR THEIR PRODUCTION - The present invention relates to a porous material comprising
| 2010-07-01 |
20100168261 | FOAM AND FABRICATION METHOD THEREOF AND BUFFER MATERIALS COMPRISING THE SAME - Foam is provided. The foam includes starch, wood flour, a chemical auxiliary and resin, wherein the resin has a weight ratio exceeding 50%. The invention also provides a method for fabricating the foam. The method includes providing a foam raw material including starch, wood flour, a chemical auxiliary and resin, wherein the resin has a weight ratio exceeding 50%, blending the foam raw material and a foaming fluid to form a blend, and performing a foaming process to form foam. | 2010-07-01 |
20100168262 | PROCESS FOR PRODUCING FLEXIBLE POLYURETHANE FOAM - To provide a process for producing a flexible polyurethane foam, which comprises reacting a polyol compound and a polyisocyanate compound in an open system substantially without using a silicone foam stabilizer. | 2010-07-01 |
20100168263 | FLAME-RETARDED STYRENE-BASED RESIN COMPOSITIONS - Disclosed is a flame-retardant styrene resin composition. The composition comprises 100 parts by weight of a styrene resin, 0.5 to 10 parts by weight of a brominated flame-retarder which has a bromine content of 60% by weight or higher, and 0.005 to 0.5 part by weight of urea, thiourea or an N-substituted derivative thereof. By using an urea compound concomitantly, the amount of the brominated flame-retarder required for achieving a desired flame retardancy level can be reduced. | 2010-07-01 |